Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CE
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
0.25 credits
- Joyce O'Shaughnessy, MD
0.25 credits
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Project Oncology®
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
1.25 credits 10 episodes
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 credits 10 episodes
Interprofessional Coordination of Adverse Event Management
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
CME/CE
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
1.00 credit
- Amir T. Fathi, MD
- Courtney DiNardo, MD
- Brian A. Jonas, MD, PhD
1.00 credit

Medical News

Medical News
Novel Gene Therapy Shows Promise for Treating IgA Nephropathy, Purespring Therapeutics Reports
biospace.com
11/06/2024
Read more
Medical News
MRI Predictive Power Could Help Rectal Cancer Patients Avoid Invasive Surgery
sciencedaily.com
11/05/2024
Read more
Medical News
Aerobic Exercise During Chemotherapy May Improve Cognitive Function in Breast Cancer Patients
miragenews.com
11/05/2024
Read more
Medical News
AI-Driven Tool Flags High Heart Failure Risk in Diabetic Patients
utsouthwestern.edu
11/04/2024
Read more

See more news

CME/CE

High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
CME/CE
Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
1.00 credit
- Matthew S. Davids, MD, MMSc
1.00 credit
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits

Clinical Practice

Treatment Intensification in HR+/HER2- EBC: Who and When?
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Recent updates from adjuvant trials in HR+/HER2- EBC
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
Project Oncology®
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
- Betsy O'Donnell, MD
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
Project Oncology®
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
- Betsy O'Donnell, MD

Programs

How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
Project Oncology®
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
- Daniel Kwon, MD
Maximizing Adherence and Persistence via Patient Engagement
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Significance of HER2 Expression in Solid Tumors
Significance of HER2 Expression in Solid Tumors
MinuteCE®
Significance of HER2 Expression in Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits